Europeanhhm

Modulo Bio embarks on a mission to comprehensively map the intricate neuroimmune system and foster innovative therapies for neurodegenerative

Friday, June 02, 2023

Modulo Bio, a biotech startup, has recently emerged from stealth mode, announcing its presence in the field today. With a significant infusion of funding, the company aims to bring newfound hope to millions of patients grappling with debilitating neurodegenerative diseases.

In recent years, there has been growing interest in exploring the brain's immune system due to advancements in technology and neurosciences. One company at the forefront of this field is Modulo, which focuses on microglia cells. Microglia cells have the ability to either protect and repair damaged neurons or contribute to further degeneration.

Modulo has developed the Modulo Neuroimmune Platform, a proprietary system that integrates software, automation, and artificial intelligence with the latest advancements in stem cell biology and neuroscience. The company's research begins with patients, using stem cell technology to generate brain cells from individuals with different diseases. This approach allows them to create an AI-generated neuroimmune fingerprint of the disease.

The CEO of Modulo, Michael Horowitz, was motivated to tackle neurodegenerative diseases like Frontotemporal Dementia (FTD) after witnessing the impact it had on his friend's mother. The company is led by a team of experts, including Scott Patterson, the CTO, who has a background in technology, and Justin Ichida, a scientific founder with expertise in modeling ALS and FTD using patient-derived cells. The team consists of cell biologists, neuroscientists, immunologists, and
computational and drug development experts.

Modulo has already identified promising microglia targets and has developed candidate treatments for diseases such as Amyotrophic Lateral Sclerosis (ALS) and FTD. Reprogramming microglia is seen as a key strategy in combating neurodegenerative diseases. By identifying targets on microglia that can shift them into protective states, Modulo aims to leverage the natural functions of the neuroimmune system to protect and repair neurons.

In addition to developing effective treatments, Modulo's broader vision is to map the entire neuroimmune system to gain a better understanding of how neurodegenerative diseases are interconnected. They aim to create multi-layered maps of cellular systems using AI, which can accurately predict the effects of genetic mutations, drugs, and their combinations on cells like microglia. By embracing the complexity of the neuroimmune system, Modulo aims to discover drugs that can have a broad impact across various neurodegenerative diseases.


Source: businesswire.com

Harvard Medical School - Leadership in Medicine Southeast Asia47th IHF World Hospital CongressHealthcare Innovation & Transformation SummitHealthcare CNO SummitHealthcare CMO SummitThe Healthcare Patient Experience & Engagement Summit 2024